Controlling dosages of drugs like THC is key to the experience of cannabis consumption, says Canadian company
published on July 31, 2018 by Perrin Grauer in StarMetro Vancouver
VANCOUVER—With cannabis legalization just around the corner, one Canadian company is calling for the inclusion of cannabis concentrates in Bill C-45, the so-called “Cannabis Act.”
Josh Campbell, president of cannabis company Dosist Canada, says in omitting concentrates from legalization, consumers are being denied a method for consistent delivery of THC and CBD — the two most commonly sought-after drugs contained in the cannabis plant.
“When we talk about dose, we’re talking about a controlled, repeatable experience,” Campbell told StarMetro in an email. “Without that. you lose predictability and control – the cornerstones of a safe and therapeutic experience. Dose control is critical for responsible use.”
Campbell and Dosist recently began a campaign — called “Not Available in Canada” — to encourage Canadians to apply political pressure in favour of expediting legalization of dose-controlled products like concentrates.
Cannabis edibles, another class of products for which dose-control is easier to achieve, will also remain illegal after Oct. 17 — the date recreational cannabis is set to become legal.
Cannabis, like any plant, may express its chemical properties in unpredictable ways even when grown under consistent conditions, said Campbell. Tetrahydrocannabinol (THC) and cannabidiol (CBD) content can vary between plants, or between generations of plants. A consumer who has one experience with a particular cannabis strain may find she has a different experience with that same strain at a later date.